Semaglutide in patients with obesity-related heart failure and type 2 diabetes

MN Kosiborod, MC Petrie, BA Borlaug… - … England Journal of …, 2024 - Mass Medical Soc
Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …
被引用次数：146 相关文章

Semaglutide in patients with obesity-related heart failure and type 2 diabetes

MN Kosiborod, MC Petrie, BA Borlaug… - New England Journal …, 2024 - eprints.gla.ac.uk
BACKGROUND Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

MN Kosiborod, MC Petrie, BA Borlaug… - … England Journal of …, 2024 - publicum.umed.lodz.pl
BACKGROUND Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

MN Kosiborod, MC Petrie, BA Borlaug, J Butler… - 2024 - pubmed.ncbi.nlm.nih.gov
Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

MN Kosiborod, MC Petrie… - New England …, 2024 - researchinformation.amsterdamumc …
BACKGROUND Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

MN Kosiborod, MC Petrie, BA Borlaug… - The New England …, 2024 - europepmc.org
Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

[引用][C] Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

MN Kosiborod, MC Petrie… - New England …, 2024 - Massachusetts Medical Society